DWTXStock
Verdicts genuinely change. Free email alert the moment DWTX's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $40.5M as of 2026-11-17.
Business activity: cleared (no excluded categories detected)
AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.29% | 30.00% | Pass(29.7pp buffer) |
| Interest-bearing investments | 12.21% | 30.00% | Pass(17.8pp buffer) |
Usmani Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.16% | 33.00% | Pass(32.8pp buffer) |
| Interest-bearing investments | 6.54% | 33.00% | Pass(26.5pp buffer) |
| Non-liquid assets | 93.46% | at least 20.00% | Pass(73.5pp above the floor) |
MSCI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.16% | 33.33% | Pass(33.2pp buffer) |
| Cash + interest-bearing securities | 6.54% | 33.33% | Pass(26.8pp buffer) |
| Accounts receivable | 6.54% | 33.33% | Pass(26.8pp buffer) |
FTSE Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 6.54% | 33.33% | Pass(26.8pp buffer) |
| Accounts receivable | 6.54% | 50.00% | Pass(43.5pp buffer) |
Dow Jones Islamic Market Fail from an earlier screen 3 of 3 ratios pass
This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.31% | 33.00% | Pass(32.7pp buffer) |
| Cash + interest-bearing securities | 13.04% | 33.00% | Pass(20.0pp buffer) |
| Accounts receivable | 0.00% | 33.00% | Pass(33.0pp buffer) |
S&P Shariah Fail from an earlier screen 3 of 3 ratios pass
This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.42% | 33.00% | Pass(32.6pp buffer) |
| Cash + interest-bearing securities | 17.59% | 49.00% | Pass(31.4pp buffer) |
| Accounts receivable | 0.00% | 49.00% | Pass(49.0pp buffer) |
MSCI M-Series Fail from an earlier screen 3 of 3 ratios pass
This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.42% | 33.33% | Pass(32.9pp buffer) |
| Cash + interest-bearing securities | 17.59% | 33.33% | Pass(15.7pp buffer) |
| Accounts receivable | 17.59% | 49.00% | Pass(31.4pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
The numbers the ratios are built from
Read from DWTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | not measured | — | — |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $4.9M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $75.6M | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $40.5M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $19.8M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $26.1M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2026-09-30 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-17.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$75.6M
Assets· balance sheet as of 2026-09-30 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 -
Cash and interest-bearing securities$4.9M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· balance sheet as of 2026-09-30 -
Receivables$0
no receivables tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2026-09-30 -
Market cap$40.5MMarket-data quote at screen time, 2026-11-17 · not a filing figure, so no link
What changed, and when
Verdict history for DWTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for DWTX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Israel Englander | Millennium Management | $1M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.00 | NEUTRAL |
| Stochastic %K (14) | 38.17 | NEUTRAL |
| CCI (20) | -58.05 | NEUTRAL |
| Williams %R (14) | -61.83 | NEUTRAL |
| MACD (12,26,9) | 0.01 | BUY |
| ROC (10) | 4.85 | BUY |
| Momentum (10) | 0.05 | BUY |
| EMA (10) | 1.12 | SELL |
| SMA (10) | 1.14 | SELL |
| EMA (20) | 1.17 | SELL |
| SMA (20) | 1.15 | SELL |
| EMA (30) | 1.23 | SELL |
| SMA (30) | 1.19 | SELL |
| EMA (50) | 1.34 | SELL |
| SMA (50) | 1.34 | SELL |
| EMA (100) | 1.59 | SELL |
| SMA (100) | 1.60 | SELL |
| EMA (200) | 2.15 | SELL |
| SMA (200) | 1.86 | SELL |
About DWTX
Healthcare · Biotechnology
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | RANGING | 21 |
| 🕐 1H | RANGING | 85 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.